Masitinib meets mastocytosis endpoints

AB Science S.A. (Euronext:AB) said masitinib met all six co-primary endpoints in a Phase IIa trial to treat systemic and cutaneous mastocytosis. Specifically, the tyrosine kinase inhibitor significant...